Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Muik

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Advances in Therapy|June 30, 2022
Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 TrialJingxin Li, Ai-Min Hui, Xiang Zhang, et al.
The Lancet Regional Health. Western Pacific|September 19, 2022
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trialAi-Min Hui, Jingxin Li, Li Zhu, et al.
Science Immunology|November 15, 2022
Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and miceAlexander Muik, Bonny Gaby Lui, Maren Bacher, et al.
Nature Communications|December 5, 2025
Immunologic and biophysical features of the BNT162b2 JN.1 and KP.2 adapted COVID-19 vaccinesWei Chen, Kristin R Tompkins, Ian W Windsor, et al.
Cancer Discovery|February 17, 2022
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid TumorsAlexander Muik, Elena Garralda, Isil Altintas, et al.
NPJ Vaccines|November 20, 2024
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccineKayvon Modjarrad, Ye Che, Wei Chen, et al.
Nature|September 30, 2020
COVID-19 vaccine BNT162b1 elicits human antibody and T<sub>H</sub>1 T cell responsesUgur Sahin, Alexander Muik, Evelyna Derhovanessian, et al.
Nature|May 27, 2021
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humansUgur Sahin, Alexander Muik, Isabel Vogler, et al.
Nature|February 1, 2021
BNT162b vaccines protect rhesus macaques from SARS-CoV-2Annette B Vogel, Isis Kanevsky, Ye Che, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Advances in Therapy|June 30, 2022
Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 TrialJingxin Li, Ai-Min Hui, Xiang Zhang, et al.
The Lancet Regional Health. Western Pacific|September 19, 2022
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trialAi-Min Hui, Jingxin Li, Li Zhu, et al.
Science Immunology|November 15, 2022
Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and miceAlexander Muik, Bonny Gaby Lui, Maren Bacher, et al.
Nature Communications|December 5, 2025
Immunologic and biophysical features of the BNT162b2 JN.1 and KP.2 adapted COVID-19 vaccinesWei Chen, Kristin R Tompkins, Ian W Windsor, et al.
Cancer Discovery|February 17, 2022
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid TumorsAlexander Muik, Elena Garralda, Isil Altintas, et al.
NPJ Vaccines|November 20, 2024
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccineKayvon Modjarrad, Ye Che, Wei Chen, et al.
Nature|September 30, 2020
COVID-19 vaccine BNT162b1 elicits human antibody and T<sub>H</sub>1 T cell responsesUgur Sahin, Alexander Muik, Evelyna Derhovanessian, et al.
Nature|May 27, 2021
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humansUgur Sahin, Alexander Muik, Isabel Vogler, et al.
Nature|February 1, 2021
BNT162b vaccines protect rhesus macaques from SARS-CoV-2Annette B Vogel, Isis Kanevsky, Ye Che, et al.
Pageof 5